GlucoTrack
GCTK
6 hedge funds and large institutions have $103K invested in GlucoTrack in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 3 → 6 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
23% less capital invested
Capital invested by funds: $133K → $103K (-$30.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$95.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.2K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$19.1K |
| 4 |
Renaissance Technologies
New York
|
+$19.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.43K |
GCTK Hedge Fund Activity: Q4 2024 in Review
6 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q4 2024, worth a combined $103K — down 23% from $133K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GCTK positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $95.3K. The largest seller was UBS Group, cutting an estimated $7.43K.
- 6 institutional investors held GlucoTrack (GCTK) as of Q4 2024, up from 3 in Q3 2024.
- Funds reported $103K of GlucoTrack stock for Q4 2024, down 23% quarter-over-quarter.
- 3 funds opened new GlucoTrack positions in Q4 2024 and 0 closed out, a net change of +3 holders.
- The largest GlucoTrack buyer in Q4 2024 was XTX Topco, an estimated $95.3K added.
- The largest GlucoTrack seller in Q4 2024 was UBS Group, an estimated $7.43K sold.
Based on aggregated 13F filings for Q4 2024.